GlassScriptPhysician profile
Don Manarang
NPI 1205833860
$1,860.57
in general payments reported to CMS, 2019-2025
28 companies · $33.63 in 2025
The $33.63 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $134 · 2021: $281 · 2022: $257 · 2023: $604 · 2024: $550 · 2025: $33.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.95 | 2021-2024 | |
| Indivior INC. | $152.99 | 2020-2024 | Perseris |
| Lilly USA, LLC | $146.40 | 2022-2024 | Mounjaro, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.91 | 2020-2022 | |
| Novo Nordisk INC | $94.63 | 2021-2024 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $86.99 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.84 | 2021 | |
| Exact Sciences Corporation | $60.85 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $53.64 | 2022-2024 | Auvelity |
| Sumitomo Pharma America, INC. | $40.28 | 2023 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $39.86 | 2024-2025 | Rexulti, Abilify Maintena |
| Gilead Sciences, INC. | $33.52 | 2020-2021 | |
| Amgen INC. | $32.29 | 2021-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $29.55 | 2024 | |
| Sanofi-Aventis U.S. LLC | $28.96 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $25.64 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $20.34 | 2024 | Spravato |
| Pfizer INC. | $19.91 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.87 | 2023 | Gvoke Hypopen |
| Alfasigma USA, INC. | $19.63 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.98 | 2022 | |
| Nevro Corp. | $16.71 | 2024 | Senza |
| Supernus Pharmaceuticals, INC. | $15.21 | 2021 | |
| Philips North America LLC | $15.02 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.57 | 2025 | Cobenfy |
| Novartis Pharmaceuticals Corporation | $13.51 | 2023 | |
| Phathom Pharmaceuticals, INC. | $13.39 | 2024 | Voquezna |
| Arbor Pharmaceuticals, INC. | $13.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Manarang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.